CA2704446A1

CA2704446A1 - Corps mimetiques se liant au recepteur de la melanocortine, compositions, procedes et utilisations

Corps mimetiques se liant au recepteur de la melanocortine, compositions, procedes et utilisations Download PDF

Info

Publication number: CA2704446A1
Authority: CA; Canada
Prior art keywords: seq; polypeptide; cell; melanocortin receptor; alpha
Prior art date: 2008-10-30
Legal status : Abandoned

Application number

CA2704446A

Other languages

English (en)

Inventor

Mark Cunningham

Vedrana Stojanovic-Susulic

Karyn O'neil

Chichi Huang

Jeffrey Luo

Current Assignee

Janssen Biotech Inc

Original Assignee

Individual

Priority date

2008-10-30

Filing date

2008-10-30

Publication date

2009-11-05

2008-10-30 Application filed by Individual filed Critical Individual

2008-10-30 Priority claimed from PCT/US2008/081734 external-priority patent/WO2009134281A2/fr

2009-11-05 Publication of CA2704446A1 publication Critical patent/CA2704446A1/fr

Status Abandoned legal-status Critical Current

Links

102000004378 Melanocortin Receptors Human genes 0.000 title claims abstract description 63
108090000950 Melanocortin Receptors Proteins 0.000 title claims abstract description 63
230000027455 binding Effects 0.000 title claims abstract description 53
238000000034 method Methods 0.000 title claims abstract description 27
239000000203 mixture Substances 0.000 title description 9
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 118
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 106
229920001184 polypeptide Polymers 0.000 claims abstract description 101
239000002157 polynucleotide Substances 0.000 claims abstract description 29
108091033319 polynucleotide Proteins 0.000 claims abstract description 29
102000040430 polynucleotide Human genes 0.000 claims abstract description 29
108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims description 39
102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims description 39
125000003275 alpha amino acid group Chemical group 0.000 claims description 20
239000013598 vector Substances 0.000 claims description 16
208000008589 Obesity Diseases 0.000 claims description 15
235000020824 obesity Nutrition 0.000 claims description 15
230000001404 mediated effect Effects 0.000 claims description 11
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 8
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
210000000056 organ Anatomy 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
239000012634 fragment Substances 0.000 claims description 7
206010057671 Female sexual dysfunction Diseases 0.000 claims description 6
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 6
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 6
208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
108060003951 Immunoglobulin Proteins 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
102000018358 immunoglobulin Human genes 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
201000005569 Gout Diseases 0.000 claims description 3
206010018634 Gouty Arthritis Diseases 0.000 claims description 3
230000004071 biological effect Effects 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
230000009285 allergic inflammation Effects 0.000 claims description 2
230000006931 brain damage Effects 0.000 claims description 2
231100000874 brain damage Toxicity 0.000 claims description 2
208000029028 brain injury Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000004761 fibrosis Effects 0.000 claims description 2
208000006454 hepatitis Diseases 0.000 claims description 2
208000028867 ischemia Diseases 0.000 claims description 2
230000000302 ischemic effect Effects 0.000 claims description 2
208000018191 liver inflammation Diseases 0.000 claims description 2
208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
230000004968 inflammatory condition Effects 0.000 claims 2
241000699802 Cricetulus griseus Species 0.000 claims 1
206010016654 Fibrosis Diseases 0.000 claims 1
206010061481 Renal injury Diseases 0.000 claims 1
210000001672 ovary Anatomy 0.000 claims 1
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 180
WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 66
101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 59
102100027467 Pro-opiomelanocortin Human genes 0.000 description 56
210000004027 cell Anatomy 0.000 description 45
238000006467 substitution reaction Methods 0.000 description 21
230000000694 effects Effects 0.000 description 16
102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 15
101710200814 Melanotropin alpha Proteins 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 15
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 15
150000001413 amino acids Chemical class 0.000 description 14
238000006206 glycosylation reaction Methods 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 10
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 9
230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
230000003248 secreting effect Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 7
230000037396 body weight Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 7
230000037406 food intake Effects 0.000 description 7
235000012631 food intake Nutrition 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
108010008364 Melanocortins Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000002865 melanocortin Substances 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
230000004580 weight loss Effects 0.000 description 6
108010087819 Fc receptors Proteins 0.000 description 5
102000009109 Fc receptors Human genes 0.000 description 5
102100023726 Melanocortin receptor 3 Human genes 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
230000004988 N-glycosylation Effects 0.000 description 5
108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108010069820 Pro-Opiomelanocortin Proteins 0.000 description 4
239000000683 Pro-Opiomelanocortin Substances 0.000 description 4
241000700159 Rattus Species 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000006870 function Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000013641 positive control Substances 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
102400000345 Angiotensin-2 Human genes 0.000 description 3
101800000733 Angiotensin-2 Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
102000030612 Melanocortin 5 receptor Human genes 0.000 description 3
108010088565 Melanocortin 5 receptor Proteins 0.000 description 3
208000001145 Metabolic Syndrome Diseases 0.000 description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 3
229950006323 angiotensin ii Drugs 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002523 lectin Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
238000002821 scintillation proximity assay Methods 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
-1 D-amino acids Chemical class 0.000 description 2
101100257999 Danio rerio stambpa gene Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000021663 Female sexual arousal disease Diseases 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
FFHBJDQSGDNCIV-MFVUMRCOSA-N bremelanotide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(O)=O)C1=CC=CC=C1 FFHBJDQSGDNCIV-MFVUMRCOSA-N 0.000 description 2
238000013262 cAMP assay Methods 0.000 description 2
210000003850 cellular structure Anatomy 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000024203 complement activation Effects 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
230000006334 disulfide bridging Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000000185 intracerebroventricular administration Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
241000894007 species Species 0.000 description 2
101150076714 stambp gene Proteins 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
108010013043 Acetylesterase Proteins 0.000 description 1
206010002652 Anorgasmia Diseases 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
108010053070 Glutathione Disulfide Proteins 0.000 description 1
101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024419 Libido decreased Diseases 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
101150004219 MCR1 gene Proteins 0.000 description 1
101710201349 Metallothionein B Proteins 0.000 description 1
101710094505 Metallothionein-2 Proteins 0.000 description 1
102100031347 Metallothionein-2 Human genes 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000012931 Urologic disease Diseases 0.000 description 1
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
108700034688 acetyl-norleucyl(4)-(aspartyl(5)-histidyl(6)-phenylalanyl(7)-arginyl(8)-tryptophyl(9)-lysyl(10))cyclo-alpha-MSH(4-10)amide Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000026816 acute arthritis Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000003253 alpha intermedin derivative Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
108010072543 bremelanotide Proteins 0.000 description 1
229950000740 bremelanotide Drugs 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940117229 cialis Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
239000000430 cytokine receptor antagonist Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000009429 distress Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
208000017020 hypoactive sexual desire disease Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000012004 kinetic exclusion assay Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940097443 levitra Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004777 loss-of-function mutation Effects 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004630 mental health Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
108010068617 neonatal Fc receptor Proteins 0.000 description 1
BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000118 neural pathway Anatomy 0.000 description 1
230000010004 neural pathway Effects 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
230000008884 pinocytosis Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000436 pro-erectile effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
108010017378 prolyl aminopeptidase Proteins 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000005250 spinal neuron Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000032258 transport Effects 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
229940094720 viagra Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1